cox 189 has been researched along with celecoxib in 30 studies
Studies (cox 189) | Trials (cox 189) | Recent Studies (post-2010) (cox 189) | Studies (celecoxib) | Trials (celecoxib) | Recent Studies (post-2010) (celecoxib) |
---|---|---|---|---|---|
163 | 49 | 47 | 5,273 | 843 | 2,428 |
Protein | Taxonomy | cox 189 (IC50) | celecoxib (IC50) |
---|---|---|---|
Chain A, Carbonic anhydrase II | Homo sapiens (human) | 0.021 | |
Prostaglandin E synthase | Homo sapiens (human) | 0.4825 | |
Histone deacetylase 3 | Homo sapiens (human) | 1.637 | |
Prostaglandin G/H synthase 1 | Bos taurus (cattle) | 7.9667 | |
Prostaglandin G/H synthase 2 | Bos taurus (cattle) | 0.057 | |
Cytochrome c oxidase subunit 1 | Ovis aries (sheep) | 6.5 | |
Cytochrome c oxidase subunit 2 | Ovis aries (sheep) | 0.0881 | |
Catechol O-methyltransferase | Mus musculus (house mouse) | 0.036 | |
Cytochrome c oxidase subunit 2 | Homo sapiens (human) | 0.371 | |
Carbonic anhydrase 1 | Homo sapiens (human) | 0.1555 | |
Carbonic anhydrase 2 | Homo sapiens (human) | 0.0925 | |
Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 5.271 | |
Procathepsin L | Homo sapiens (human) | 0.56 | |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 7.308 | |
Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | 0.07 | |
Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 4.295 | |
Cytochrome P450 2D6 | Homo sapiens (human) | 1 | |
Cytochrome P450 2C9 | Homo sapiens (human) | 10 | |
Calpain-2 catalytic subunit | Homo sapiens (human) | 0.002 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 1.516 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.12 | |
Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | 3.6401 | |
Prostaglandin G/H synthase 1 | Homo sapiens (human) | 3.5499 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 7.308 | |
Indoleamine 2,3-dioxygenase 1 | Mus musculus (house mouse) | 0.006 | |
Sodium-dependent serotonin transporter | Homo sapiens (human) | 6.276 | |
Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.3818 | |
Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.4028 | |
Urotensin-2 receptor | Rattus norvegicus (Norway rat) | 7.6 | |
Histone deacetylase 4 | Homo sapiens (human) | 1.637 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.03 | |
Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.6343 | |
Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 7.7 | |
Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.431 | |
Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.045 | |
Histone deacetylase 1 | Homo sapiens (human) | 1.411 | |
Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.81 | |
Carbonic anhydrase 9 | Homo sapiens (human) | 0.016 | |
Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | 0.05 | |
Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | 0.3 | |
Prostaglandin G/H synthase 1 | Canis lupus familiaris (dog) | 5.57 | |
Cyclooxygenase-2 | Canis lupus familiaris (dog) | 0.9 | |
Histone deacetylase 7 | Homo sapiens (human) | 1.637 | |
Histone deacetylase 2 | Homo sapiens (human) | 1.637 | |
Carbonic anhydrase 4 | Bos taurus (cattle) | 0.2227 | |
Polyamine deacetylase HDAC10 | Homo sapiens (human) | 1.637 | |
Histone deacetylase 11 | Homo sapiens (human) | 1.637 | |
Histone deacetylase 8 | Homo sapiens (human) | 1.637 | |
P2Y purinoceptor 12 | Rattus norvegicus (Norway rat) | 0.04 | |
Histone deacetylase 6 | Homo sapiens (human) | 1.14 | |
Histone deacetylase 9 | Homo sapiens (human) | 1.637 | |
Histone deacetylase 5 | Homo sapiens (human) | 1.637 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 19 (63.33) | 29.6817 |
2010's | 11 (36.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Bhardwaj, A; Dzandzi, J; Tietz, O; Valliant, JF; Wuest, F | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Adami, S; Berenbaum, F; Bliddal, H; Gimona, A; Lee, A; Moore, A; Navarro, F; Poor, G; Reginster, JY; Robinson, J; Tannenbaum, H; Uebelhart, D; Zacher, J | 1 |
Fricke, J; Jayawardene, S; Kellstein, D; Ott, D | 1 |
Cousin, M; Fiedorowicz-Fabrycy, IF; Gitton, X; Hawkey, CC; Hoexter, G; Nasonov, EL; Pikhlak, EG; Svoboda, P | 1 |
Curran, MP; Lyseng-Williamson, KA | 1 |
Cristofoletti, R; Fabricio, AS; Navarra, P; Souza, GE; Veiga, FH | 1 |
Beaulieu, A; Dutta, D; Paster, Z; Sheldon, E; Sloan, VS; Yu, S | 1 |
Brzosko, M; Kopsa, P; Kreisse, A; Lehmann, R; Litschig, S; Nischik, R; Sloan, VS; Thurston, H | 1 |
Hochberg, MC | 1 |
Dutta, D; Fleischmann, R; Maldonado-Cocco, J; Sheldon, E; Sloan, VS; Yu, S | 1 |
Bishop-Bailey, D; Mitchell, JA; Vojnovic, I; Warner, TD | 1 |
Burger, KJ; Fashola, TO; Krehan, G; Maeumbaed, R; Runge, H; Schell, E; Schlüter, P; Thurston, HJ; Trechsel, U; Wittenberg, RH | 1 |
Marwali, MR; Mehta, JL | 1 |
Deray, G; Montalescot, G; Sibilia, J | 1 |
Deray, G; Héloire, F; Valat, JP | 1 |
Dougados, M; Gitton, X; Moore, A; Yu, S | 1 |
Ashcroft, DM; Chen, LC | 1 |
Davis, N; Fricke, J; Krammer, G; Yu, V | 1 |
Klotz, U; Shi, S | 1 |
Fleischmann, R; Notter, M; Patel, NP; Reginster, JY; Sallstig, P; Tannenbaum, H | 1 |
Elliott, WJ | 1 |
Bakhle, YS; de Francischi, JN; dos Reis, WG; Ferreira-Alves, DL; Gassani, BC; Paiva-Lima, P; Rezende, RM | 1 |
Honjo, H; Iwamoto, K; Uwai, Y | 1 |
Harirforoosh, S; Pettit, WL; Wyatt, JE | 1 |
Hu, RW; Li, HY; Li, JS; Miao, XP; Ouyang, Q; Zhang, Y | 1 |
Anstaett, P; Ferrari, S; Gasser, G; Pierroz, V | 1 |
Hansen, SH; Skonberg, C; Syed, M | 1 |
11 review(s) available for cox 189 and celecoxib
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Membrane Proteins; Organic Chemicals; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Rheumatology; Sulfonamides; Sulfones; Treatment Outcome | 2005 |
COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies.
Topics: Animals; Blood Platelets; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Labeling; Endothelium, Vascular; Epoprostenol; Humans; Lactones; Platelet Aggregation; Product Surveillance, Postmarketing; Pyrazoles; Randomized Controlled Trials as Topic; Risk Assessment; Sulfonamides; Sulfones; Thromboxane A2 | 2006 |
[What do we know about the cardiovascular toxicity of the NSAIDs?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors | 2006 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Edema; Heart Failure; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Odds Ratio; Placebos; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors | 2006 |
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis; Pain Measurement; Patient Satisfaction; Pyrazoles; Sulfonamides | 2007 |
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones | 2007 |
Clinical use and pharmacological properties of selective COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Monitoring; Etoricoxib; Humans; Osteoarthritis; Pain; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2008 |
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Hypertension; Isoxazoles; Lactones; Pyrazoles; Pyridines; Risk; Risk Factors; Sulfonamides; Sulfones | 2010 |
Pharmacogenetics of nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Celecoxib; Cytochrome P-450 CYP2C9; Diclofenac; Humans; Ibuprofen; Indomethacin; Pharmacogenetics; Pyrazoles; Sulfonamides | 2012 |
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Sulfonamides; Sulfones | 2014 |
11 trial(s) available for cox 189 and celecoxib
Article | Year |
---|---|
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Isoenzymes; Logistic Models; Male; Membrane Proteins; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2004 |
Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Lactones; Male; Molar, Third; Organic Chemicals; Pain, Postoperative; Pyrazoles; Sulfonamides; Sulfones; Tooth Extraction; Treatment Outcome | 2004 |
Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Incidence; Male; Middle Aged; Organic Chemicals; Osteoarthritis; Peptic Ulcer; Pyrazoles; Risk Factors; Sulfonamides | 2004 |
Lumiracoxib.
Topics: Administration, Oral; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Half-Life; Humans; Male; Molecular Structure; New Zealand; Organic Chemicals; Osteoarthritis; Oxycodone; Pain; Pyrazoles; Sulfonamides; Terminology as Topic; World Health Organization | 2004 |
Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Male; Membrane Proteins; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome | 2005 |
Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib.
Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Placebos; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Pain; Pain Measurement; Prospective Studies; Pyrazoles; Sulfonamides; Treatment Outcome | 2006 |
First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].
Topics: Aged; Analgesics; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis, Knee; Pain Measurement; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome | 2006 |
Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Diclofenac; Double-Blind Method; Female; Humans; Male; Middle Aged; Osteoarthritis; Pain Measurement; Patient Satisfaction; Pyrazoles; Sulfonamides | 2007 |
Lumiracoxib 400 mg compared with celecoxib 400 mg and placebo for treating pain following dental surgery: a randomized, controlled trial.
Topics: Adolescent; Adult; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Pain Measurement; Pain, Postoperative; Placebo Effect; Pyrazoles; Sulfonamides; Time Factors; Tooth Extraction; Tooth, Impacted; Treatment Outcome | 2008 |
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
Topics: Aged; Arthralgia; Canada; Cardiovascular Diseases; Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Europe; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Osteoarthritis; Pain Measurement; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome; United States | 2008 |
9 other study(ies) available for cox 189 and celecoxib
Article | Year |
---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Design and synthesis of [(125)I]Pyricoxib: A novel (125)I-labeled cyclooxygenase-2 (COX-2) inhibitors.
Topics: Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Iodine Radioisotopes; Molecular Docking Simulation; Molecular Structure; Pyrimidines; Structure-Activity Relationship; Sulfones | 2016 |
The effects of selective and nonselective cyclooxygenase inhibitors on endothelin-1-induced fever in rats.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; Endothelin-1; Fever; Indomethacin; Injections, Intraperitoneal; Injections, Intraventricular; Intubation, Gastrointestinal; Lipopolysaccharides; Male; Organic Chemicals; Pyrazoles; Rats; Rats, Wistar; Sulfonamides | 2005 |
Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
Topics: Aspirin; Blood Platelets; Blood Proteins; Calcimycin; Calcium; Celecoxib; Cell Line; Cerebrospinal Fluid Proteins; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Humans; Indomethacin; Ionophores; Lactones; Meloxicam; Naproxen; Organ Specificity; Organic Chemicals; Protein Binding; Pyrazoles; Sodium Salicylate; Sulfonamides; Sulfones; Synovial Fluid; Thiazines; Thiazoles; Thromboxane A2 | 2006 |
Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity?
Topics: Acetazolamide; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Hyperalgesia; Inflammation; Male; Naltrexone; Narcotic Antagonists; Pain; Pain Measurement; Pain Threshold; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides | 2010 |
Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3.
Topics: Animals; Binding, Competitive; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Estrone; Etoricoxib; Humans; Inhibitory Concentration 50; Isoxazoles; Kinetics; Lactones; Methotrexate; Oocytes; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Pyrazoles; Pyridines; RNA, Complementary; Sulfonamides; Sulfones; Xenopus laevis | 2010 |
Two-photon uncageable enzyme inhibitors bearing targeting vectors.
Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Lasers; Photons | 2015 |
Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria.
Topics: Adenosine Triphosphate; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Isoxazoles; Lactones; Male; Mitochondria, Liver; Oxidative Phosphorylation; Pyridines; Rats, Sprague-Dawley; Sulfonamides; Sulfones | 2016 |